www.pacermonitor.com/public/case/27866570/Johnson_et_al_v_Pfizer_Inc_et_al

Apr 17, 2019 ... Johnson et al v. Pfizer Inc. et al (1:19-cv-03431), New York Southern District Court, Filed: 04/17/2019 - PacerMonitor Mobile Federal and ...

law.justia.com/cases/federal/district-courts/illinois/ilndce/1:2016cv07142/329069/59

Mar 14, 2019 ... United States of America et al v. Pfizer, Inc. et al, No. 1:2016cv07142 - Document 59 (N.D. Ill. 2019) case opinion from the Northern District of ...

law.justia.com/cases/federal/appellate-courts/ca7/17-2056/17-2056-2018-01-19.html

Jan 19, 2018 ... In Wyeth v. Levine, the Supreme Court held that claims against a manufacturer of a brand-name prescription drug for failure to warn adequately ...

www.courts.ca.gov/opinions-slip.htm?Courts=R

Hacker v. Homeward Residential, Inc. 4/10/18 CA2/1 Case Details. Jul 25 .... Corp. v. Super. Ct. 8/31/17 CA2/3 Case Details. Nov 30, 2017, A147564 [PDF] [ DOC] ...... Roe 58 v. Doe 1 et al. ..... Clayworth v. Pfizer, Inc. 8/19/08 CA1/2 Case Details ...... Siebel v. Mittlesteadt 5/6/04 CA6 Case Details. May 03, 2004, E033920M

www.krcomplexlit.com/wp-content/uploads/2015/09/PlsUnoppMotFinalApprovalStlmntAgmntCertStlmntClass102041717.pdf

Sep 17, 2015 ... Boyd v. Coventry Health Care Inc.,. 299 F.R.D. 451 (D. Md. 2014) ...... John Langbein et al., PENSION AND EMPLOYEE BENEFIT LAW 187- ..... attending the Fairness Hearing); Ex. J, March 22, 2017 Letter from Richard Siebel ( requesting ...... In re Lipitor Antitrust Litigation (D.N.J): Plaintiffs allege that Pfizer,  ...

www.pfizersecuritieslitigationsettlement.com/docs/Caliendo%20Declarationin%20Support%20of%20Final%20Approval%20of%20Class%20Action%20Settlement%20and%20Award%20of%20Fees%20and%20Ex.pdf

Nov 11, 2016 ... defendants Pfizer Inc. (“Pfizer”), Henry A. McKinnell, Ph.D. (Pfizer's former .... “ signals” of increased CV risk for Celebrex all along. ... of various Daubert motions , and finally, (v) the presentation and cross ...... Claghorn, et al v. ...... G&E effected a sea change in the compensation policies of Siebel Systems, a.

academic.oup.com/cid/article/43/2/215/334446

Anidulafungin (Eraxis; Pfizer) is the newest echinocandin antifungal to be approved by the US ..... Merck, Sharp, & Dohme Ltd ... Siebel. NL. , et al. Safety and pharmacokinetics of anidulafungin in pediatric patients with ... et al. Anidulafungin vs. fluconazole for treatment of candidemia and invasive candidiasis [abstract 1040].

www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207795Orig1s000PharmR.pdf

Aug 1, 2017 ... Incorporated (B & L; a wholly-owned subsidiary of Valeant Pharmaceuticals. International)” ... PF-03187207 (Pfizer) ...... The results of this report were also published in the Cavet et al. .... Feelisch M, Kotsonis P, Siebe J, Clement B, Schmidt HH. ... Chiroli, V., Chong, W.K., Carreiro, S.T., and Ongini, E. 2011.

www.cell.com/fulltext/S0896-6273(08)00169-4

May 7, 2008 ... Charron et al., 2003 ... Kaprielian et al., 2001 ... Kidd et al., 1999 ...... We thank L. Case, C. Goodman, A. Jaworski, C.W. Siebel, A. Yaron, and J. Zou for helpful discussions ... Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. .... 2008 Elsevier Inc. Published by Elsevier Inc.